TheraRadar
← Back
Data updated: Mar 29, 2026

MIRUM

GastroenterologyInfectious Disease
Pharma

MIRUM is a pharmaceutical company focused on Gastroenterology, Infectious Disease. Key products include CHOLBAM.

2015
Since
3
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

CHOLBAM
cholic acid
FXR 5 indications · 2015
LIVMARLI
maralixibat chloride
IBAT 3 indications · 2021
CTEXLI
chenodiol
CYP7A1 1 indications · 2025

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

LIVMARLI 2025-04-10
Type 3 - New Dosage Form
CTEXLI 2025-02-21
Type 5 - New Formulation or New Manufacturer
LIVMARLI 2024-11-08
Labeling
LIVMARLI 2024-07-24
Efficacy
LIVMARLI 2024-07-24
Manufacturing (CMC)
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Gastroenterology 58%
1 drugs Phase 3: 3 Phase 2: 2
Infectious Disease 42%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 2

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Gastroenterology
Bristol-Myers Squibb big-pharma
Gastroenterology, Infectious Disease
APOTHECON specialty
Infectious Disease, Gastroenterology
Gilead Sciences biotech
Infectious Disease, Gastroenterology
WAYLIS THERAP big-pharma
Infectious Disease, Gastroenterology